Colorectal Cancer, Dysgeusia, Oral Complications of Chemotherapy
Conditions
Brief summary
The purpose of this research study is to determine if using a lactoferrin supplement will improve taste perception. Lactoferrin is a type of protein that is naturally produced in the body and is commonly found in saliva.
Detailed description
PRIMARY OBJECTIVES: I. To assess the impact of lactoferrin (bovine lactoferrin) supplementation on self-reported taste and smell disturbances in patients with colorectal cancer receiving oxaliplatin-based chemotherapy SECONDARY OBJECTIVES: I. To assess the impact of lactoferrin supplementation on the baseline lipid peroxidation byproducts in saliva in these patients as measured by the thiobarbituric acid-reactive substances (TBARs) assay. II. To assess the impact of lactoferrin supplementation on the ability of these patients to generate increased lipid peroxidation byproducts when challenged with a weak iron containing solution. III. To assess the impact of lactoferrin supplementation on self-reported general quality of life and on specific self-reported anorexia/cachexia issues in patients with established chemotherapy-induced taste disturbances. IV. To assess the incidence of vitamin D deficiency in patients with oxaliplatin-based therapy induced taste changes OUTLINE: Patients receive bovine lactoferrin orally (PO) (rinse or tablet) thrice daily (TID) for 1 month. Treatment continues in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up at 2 and 4 weeks.
Interventions
OTHERquestionnaire administration
Ancillary studies
PROCEDUREquality-of-life assessment
Ancillary studies
OTHERlaboratory biomarker analysis
Correlative studies
DIETARY_SUPPLEMENTbovine lactoferrin
Given PO
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed colorectal carcinoma * There are no restrictions on the amount or types of prior therapy * Eligible patients must be receiving ongoing chemotherapy with an oxaliplatin containing-regimen which is planned to continue for at least one month following enrollment in this trial * Any dose or schedule of oxaliplatin administration is allowed as long as patients have self-reported taste disturbance that has either: * 1\) developed since the initiation of oxaliplatin-based therapy, or * 2\) a pre-existing, treatment-induced taste disturbance has subjectively worsened since initiating oxaliplatin-based therapy * Patients must have normal baseline self-reported taste perception prior to the development of colorectal carcinoma * Life expectancy of \>= 3 months * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients with a subjective history of an extreme dry mouth syndrome that prevents them from producing adequate amounts of saliva (approximately 2 mL in 15-20 min) * Patients known to be human immunodeficiency virus (HIV)-positive * Patients with any of the following conditions: untreated gastrointestinal reflux disease; untreated diabetes mellitus; active thrush; active oral infection; active mucositis * Patients who are known to be pregnant or who are breastfeeding are excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses | Approximately 1 month | Paired-tests will be used to assess the significance of these changes. Linear regression models will be used to determine which patient covariates are associated with change. Repeated measures models will also be used to assess the changes over time using all the repeated measures and contrasts will be used to assess individual pair-wise differences. Descriptive reports will consist of summary statistics (means, standard deviations, proportions, etc.). |
Secondary
| Measure | Time frame |
|---|---|
| Malondialdehyde (MDA) concentrations before and after a ferrous iron oral rinse | Approximately 2 months |
| Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire | Approximately 2 months |
| Effect of bovine lactoferrin on lipid peroxidation byproducts in saliva as measured by the TBARs assay | Approximately 2 months |
Countries
United States
Outcome results
None listed